Cargando…
Cannabinoids as anticancer drugs: current status of preclinical research
Drugs that target the endocannabinoid system are of interest as pharmacological options to combat cancer and to improve the life quality of cancer patients. From this perspective, cannabinoid compounds have been successfully tested as a systemic therapeutic option in a number of preclinical models o...
Autores principales: | Hinz, Burkhard, Ramer, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276677/ https://www.ncbi.nlm.nih.gov/pubmed/35277658 http://dx.doi.org/10.1038/s41416-022-01727-4 |
Ejemplares similares
-
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
por: Ramer, Robert, et al.
Publicado: (2022) -
Impact of Cannabinoid Compounds on Skin Cancer
por: Ramer, Robert, et al.
Publicado: (2022) -
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy
por: Ramer, Robert, et al.
Publicado: (2019) -
The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies
por: Ramer, Robert, et al.
Publicado: (2021) -
Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy
por: Tamba, Bogdan Ionel, et al.
Publicado: (2020)